Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant ChemotherapyRoland Seiler, Peter C. Black, H.A.D.M. Ashab et al.|European Urology|2017Cited by 793
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I StudySuzanne Trudel, Simon J. Harrison, Andrew Spencer et al.|Blood|2021Cited by 161